Fosun Pharma’s progress announcement on the proposed spin-off of its subsidiary and independent listing on the Main Board of The Stock Exchange of Hong Kong Limited
Securities code: 600196 Stock abbreviation: Fosun Pharma Number: Lin 2026-090
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
Regarding the proposed spin-off of subsidiaries
Announcement on the progress of independent listing on the Main Board of The Stock Exchange of Hong Kong Limited
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
1. Overview of the proposed spin-off and listing
On January 22, 2026, the 22nd meeting of the 10th Board of Directors of Shanghai Fosun Pharma (Group) Co., Ltd. (hereinafter referred to as the "Company") reviewed and approved the relevant resolution on the spin-off of its subsidiary Fosun Antgene (Chengdu) Biopharmaceutical Co., Ltd. (hereinafter referred to as "Fosun Antgene") to the main board of The Stock Exchange of Hong Kong Limited (hereinafter referred to as the "Hong Kong Stock Exchange") (hereinafter referred to as the "Proposed Spin-off and Listing"). On February 27, 2026, the relevant resolution was also reviewed and approved by the company's first extraordinary shareholders' meeting in 2026. For the above details, please refer to the relevant announcements published by the Company in China Securities Journal, Shanghai Securities News, Securities Times and the Shanghai Stock Exchange website (http://www.sse.com.cn) on January 23 and February 28, 2026.
2. Progress of proposed spin-off and listing
The Company has applied to the Hong Kong Stock Exchange for approval of the proposed spin-off and listing in accordance with Application Guideline 15 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (hereinafter referred to as the “Listing Rules of the Hong Kong Stock Exchange”), and the Hong Kong Stock Exchange has confirmed that the Company can proceed with the proposed spin-off and listing.
On June 26, 2026, the Company received notification that Fosun Entjin had submitted a listing application to the Hong Kong Stock Exchange through its joint sponsor on that day to apply for the listing and trading of its H shares on the Main Board of the Hong Kong Stock Exchange.
The application version of Fosun Entejin's prospectus (some information has been obscured as required, hereinafter referred to as the "application version") can be viewed and downloaded on the website of the Hong Kong Stock Exchange (https://www1.hkexnews.hk/app/appindex.html).
The Application Proof contains, among other things, certain business and financial information about Fosun Entkin. Shareholders of the Company and potential investors should note that the Application Proof is a draft version and the information contained therein is not yet complete and may require significant changes. The Company will not assume any obligation or responsibility for the content of the application version.
Fosun Antkin proposes that the initial size of the issuance shall not exceed 25% of its enlarged total share capital immediately after the issuance (before the over-allotment option is exercised), and has granted the global coordinator/bookrunner an over-allotment right of no more than 15% of the above-mentioned initial issuance size. It is expected that after the completion of the proposed spin-off and listing, Fosun Antjin will remain a controlled subsidiary of the company.
3. Other instructions
In connection with the proposed issuance of Fosun Antkin, the price of Fosun Antjin's H shares may be stabilized in accordance with the Securities and Futures (Price Stabilization) Rules (Chapter 571W of the Laws of Hong Kong). If the proposed spin-off and listing proceeds, details of any proposed price stabilization measures and how they will be regulated by the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) will be set out in the prospectus published by Fosun Antkin in Hong Kong in connection with the proposed issue.
As of the date of this announcement (i.e. June 26, 2026), the proposed spin-off and listing is subject to filing or approval by, among other things, the China Securities Regulatory Commission, the Hong Kong Stock Exchange and other relevant regulatory authorities, and will depend on market conditions and other factors; and there is no guarantee as to when the aforementioned filing or approval will be completed. Accordingly, the Company's shareholders and potential investors are required to exercise caution when dealing in the Company's securities. Any person who is in doubt about his situation or any action he should take is advised to consult his or her own professional advisers. The company will perform its information disclosure obligations in a timely manner in accordance with the requirements of relevant laws and regulations and in conjunction with the progress of the proposed spin-off and listing.
Announcement is hereby made.
Board of Directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
June 26, 2026